Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Multicenter, Single Arm, Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a, Open-Label, Multicenter, Single Arm, Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acrixolimab (Primary)
  • Indications Adenocarcinoma; Anal cancer; Brain metastases; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Penile cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Y-Biologics

Most Recent Events

  • 01 Nov 2023 According to Lunit media release, the study will be presented at the upcoming SITC (Society for Immunotherapy of Cancer) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California.
  • 01 Dec 2022 Planned End Date changed from 23 May 2023 to 31 Mar 2023.
  • 01 Dec 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top